Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bristol-Myers Squibb Co has a Cash Ratio of 0.55. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Bristol-Myers Squibb Co's Cash Ratio or its related term are showing as below:
XSWX:BMY'
s Cash Ratio Range Over the Past 10 Years
Min: 0.29 Med: 0.69 Max: 3.1
Current: 0.55
During the past 13 years, Bristol-Myers Squibb Co's highest Cash Ratio was 3.10. The lowest was 0.29. And the median was 0.69.
XSWX:BMY's Cash Ratio is ranked worse than 52.36% of 974
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs XSWX:BMY: 0.55
Bristol-Myers Squibb Co (XSWX:BMY) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Bristol-Myers Squibb Co Cash Ratio Related Terms
Bristol-Myers Squibb Co Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BMY vs PFE, GILD, AMGN: Cash Ratio Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (XSWX:BMY) has a Cash Ratio of 0.55 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Bristol-Myers Squibb Co and its competitors. This is 20% below median its historical median of 0.69. Over the past decade, Bristol-Myers Squibb Co's Cash Ratio has ranged from 0.29 to 3.10. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #510 out of 974 companies in the Drug Manufacturers industry, placing it in the top 52.4%.
Is Bristol-Myers Squibb Co's Cash Ratio too high?
Bristol-Myers Squibb Co's current Cash Ratio of 0.55 is 20% below median its 10-year median of 0.69. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 3.10. The Drug Manufacturers industry median Cash Ratio is 0.61. Bristol-Myers Squibb Co's value of 0.55 is 9.8% below this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #510 out of 974 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bristol-Myers Squibb Co has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Cash Ratio compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #510 out of 974 companies for Cash Ratio. This places Bristol-Myers Squibb Co in the lower half of its industry. The industry median Cash Ratio is 0.61. Bristol-Myers Squibb Co's value of 0.55 is 9.8% below this benchmark. Historically, Bristol-Myers Squibb Co's own Cash Ratio has ranged from 0.29 to 3.10 over the past decade. While the company's 10-year median is 0.69 vs. the industry median of 0.61, Bristol-Myers Squibb Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.61, based on 974 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current Cash Ratio of 0.55 is 9.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Bristol-Myers Squibb Co and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current Cash Ratio is 0.55, which is 20% below median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Bristol-Myers Squibb Co (XSWX:BMY) has a current Cash Ratio of 0.55. The stock's GF Value™ is CHF45.07, compared to a current price of CHF50.31 — trading 11.6% above its estimated fair value. The current Cash Ratio is 0.55, which is 20% below median its 10-year median of 0.69 and 9.8% below the Drug Manufacturers industry median of 0.61. Bristol-Myers Squibb Co's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current Cash Ratio is 0.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of CHF50.31 is trading 11.6% above its estimated GF Value™ of CHF45.07.
Key valuation signals for XSWX:BMY:
Cash Ratio: 0.55 (20% below median its 10-year median of 0.69)
GF Value™: CHF45.07 vs. price of CHF50.31 (11.6% above fair value)
Industry Position: 9.8% below the Drug Manufacturers median (#510 of 974)
No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
78GF Score
Get the complete analysis for XSWX:BMY
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BMY has been successfully added to your 
